This Open Access edition of the European Society for Blood and Marrow Transplantation (EBMT) handbook addresses the latest developments and innovations in hematopoietic stem cell transplantation and cellular therapy. Consisting of 93 chapters, it has been written by 175 leading experts in the field.
Discussing all types of stem cell and bone marrow transplantation, including haplo-identical stem cell and cord blood transplantation, it also covers the indications for transplantation, the management of early and late complications as well as the new and rapidly evolving field of cellular therapies.
This book provides an unparalleled description of current practices to enhance readers' knowledge and practice skills.
Auflage
Sprache
Verlagsort
Verlagsgruppe
Springer International Publishing
Zielgruppe
Editions-Typ
Illustrationen
18
38 farbige Abbildungen, 18 s/w Abbildungen
XL, 702 p. 56 illus., 38 illus. in color.
Maße
Höhe: 25.4 cm
Breite: 17.8 cm
Gewicht
ISBN-13
978-3-030-02277-8 (9783030022778)
DOI
10.1007/978-3-030-02278-5
Schweitzer Klassifikation
Enric Carreras, MD, PhD, the handbook Project Leader is Director of the Spanish Bone Marrow Donor Registry, Josep Carreras Foundation and Leukemia Research Institute in Barcelona, Spain
Carlo Dufour, MD, PhD, is Chairperson SAAWP Education Representative at Scientific Council Education, Director Hematology Unit, ay IRCCS Giannina Gaslini, Genoa, Italy
Nicolaus Kröger MD, PhD, is the current EBMT President, Scientific Council Chair, Professor of Medicine and Medical Director of the Department of Stem Cell Transplantation at the University Medical Center, Hamburg - Eppendorf, Germany
Mohamad Mohty, MD, PhD , is past-president of the EBMT, Chairperson ALWP, Professor of Hematology and Head of the Hematology and cellular therapy Department at the Saint-Antoine Hospital and University Pierre & Marie Curie, Paris, France
Part 1. Introduction.- 1. HSCT: Historical perspective.- 2. The EBMT: History, present and future.- 3. The role of unrelated donor registries in HSCT.- 4. The HSCT Unit.- 5. JACIE accreditation of HSCT programs.- 6. Statistical methods in HSCT and Cellular Therapies.- Part 2. Biological aspects.- 7. Biological properties of HSC: scientific basis for HSCT.- 8. Biological properties of cells other than HSC.- 9. Histocompatibility.- 10. Clinical & biological concepts for mastering Immune reconstitution after HSCT: towards practical guidelines and greater harmonization.- Part 3. Methodology and clinical aspects.- 11. Evaluation and counselling of candidates.- 12. Donor selection for adults and pediatrics.- 13. Conditioning.- 14. Bone marrow harvesting for HSCT.- 15. Mobilization and collection of HSC.- 16. Collection of HSC in children.- 17. Processing, cryopreserving, and controlling the quality of HSCs.- 18. Procurement and management of cord blood.- 19. Graft manipulation.- 20. Documentation of engraftment and chimerism after HSCT.- 21. Short and long-term controls after HSCT.- Part 4. General management of the patient.- 22. Vascular access.- 23. Transfusion support.- 24. Nutritional support.- 25. GVHD prophylaxis (immunosuppression).- 26. Management ATG (SIRS).- 27. Infections control and isolation procedures.- 28. General management of the patient; Specific aspects of children.- 29. Vaccinations.- 30. Psychological morbidity and support.- 31. Clinical relevant drug interactions in HSCT.- 32. Role of nursing in HSCT.- 33. Ethical issues in HSCT.- 34. Quality of life assessment after HSCT for pediatric and adults.- Part 5. HSCT complications and management.- 35. Neutropenic fever.- 36. Bacterial infections.- 37. Invasive fungal infections.- 38. Viral infections .- 39. Other life-threatening infections.- 40. Bleeding and thrombotic complications.- 41. Graft failure.- 42. Early complications of endothelial origin.- 43. Acute Graft-versus-Host Disease.- 44. Chronic Graft-versus-Host Disease.- 45. Post-transplant lymphoproliferative syndromes.- 46. Iron overload.- 47. Secondary neoplasia (other than PTLPS).- Part 6. Specific organ complications.- 48. Ocular and oral complications.- 49. Hepatic complications.- 50. Gastrointestinal complications.- 51. Hemorrhagic cystitis and renal dysfunction.- 52. Non-infectious pulmonary complications.- 53. Neurological complications.- 54. Skin, hair and musculoskeletal complications.- 55. Cardiovascular diseases and metabolic syndrome.- 56. Endocrine disorders, fertility and sexual health.- Part 7. Prevention and management of relapse.- 57. Monitoring MRD in ALL and AML.- 58. Preventing/treating relapse with drugs.- 59. Delayed transfer of immune cells, or the art of Donor Lymphocyte Infusion.- 60. Cellular therapy with engineered T cells, efficacy and side effects.- 61. Mechanisms of Immune resistance.- 62. Regulatory Aspects of ATMP versus minimally manipulated immune cells.- Part 8. Specific modalities of HSCT and management.- 63. At-home HSCT.- 64. Umbilical cord blood transplantation in children and adults.- 65. Haploidentical HSCT.- 66. Photopheresis in adults and pediatrics.- 67. Overweight and obese patients.- 68. HSCT in elderly patients.- Part 9. Indications and results.- 69. Acute Myeloid Leukemia in adults.- 70. Acute Myeloid Leukemia in children.- 71. Acute Lymphoblastic Leukemia in adults.- 72. Acute lymphoblastic leukemia in children and adolescents.- 73. Myelodysplastic syndromes.- 74. Pediatric MDS including Refractory Cytopenia and Juvenile Myelomonocytic Leukemia.- 75. Myelodysplastic/myeloproliferative neoplasms.- 76. Myeloproliferative neoplasms.- 77. Severe aplastic anemia and PNH.- 78. Fanconi anemia and other hereditary Bone Marrow Failure syndromes.- 79. Hemoglobinopathies (Sickle Cell Disease and Thalassemia).- 80. Multiple myeloma.- 81. Systemic light chain amyloidosis.- 82. POEMS syndrome and disease produced by other monoclonal immunoglobulins.- 83. Follicular lymphoma.- 84. Chronic lymphocytic leukemia.- 85. Diffuse large B cell lymphoma.- 86. Mantle cell lymphoma.- 87. Other T- and B-aggressive lymphomas and lymphomas associated to HIV.- 88. Classical Hodgkin's lymphoma.- 89. Primary immunodeficiencies.- 90. Inborn error of metabolism and osteopetrosis.- 91. Autoimmune disease.- 92. Solid tumors
